| Literature DB >> 24663115 |
Khanitha Pudhom1, Thapong Teerawatananond2, Supichar Chookpaiboon3.
Abstract
Three new spirobisnaphthalenes (1-3) were isolated from the mangrove-derived fungus Rhytidhysteron sp., together with five known derivatives (4-8). The structures of the compounds were established on the basis of extensive spectroscopic data, and the relative configurations of their stereogenic carbons were determined by a single-crystal X-ray crystallographic analysis. Compounds 3-5 displayed cytotoxicity against both cancer cell lines, MCF-7 and CaSki, while 2 was active only on CaSKi cells.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24663115 PMCID: PMC3967209 DOI: 10.3390/md12031271
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1‒8 isolated from fungus Rhytidhysteron sp.
Figure 2(a) Key HMBC and 1H-1H COSY correlations of rhytidone A (1); (b) ORTEP diagram of the 5-acetate derivative of 1 (1a).
NMR spectroscopic data of compounds 1–3.
| No. | 1 a | 2 b | 3 b | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| 1 | - | 104.4 | - | 104.4 | - | 104.4 |
| 2 | 1.73, m | 25.6 | 1.95, m | 25.6 | 1.94, m | 25.6 |
| 3 | 1.53, m | 28.2 | 1.75, m | 26.5 | 1.72, m | 26.6 |
| 4 | 4.16, br s | 61.2 | 4.54, br s | 62.9 | 4.52, br s | 62.9 |
| 4a | 1.97, ddd (12.8, 10.0, 2.4) | 42.9 | 3.31, d (13.6) | 49.0 | 3.27, dd (13.2, 1.6) | 48.9 |
| 5 | 3.70, br s | 68.8 | - | 212.2 | - | 211.8 |
| 6 | 1.75, m | 35.7 | 3.13, br s | 44.2 | 3.05, m | 41.2 |
| 7 | 4.21, br s | 66.9 | 4.43, t (3.2) | 71.3 | 3.89, m | 80.1 |
| 8 | 3.93, m | 63.3 | 4.77, d (3.2) | 67.4 | 4.88, br d (3.6) | 65.1 |
| 8a | 2.44, dd (12.8, 1.6) | 38.6 | 3.17, br s | 41.5 | 3.03, m | 41.9 |
| 1' | - | 146.5 | - | 147.3 | - | - |
| 2' | 6.96, d (7.2) | 109.4 | 6.94, d (7.2) | 109.8 | 6.96, d (7.6) | 109.8 |
| 3' | 7.45, t (7.6) | 127.6 | 7.43, t (8.0) | 127.8 | 7.44, t (7.6) | 127.7 |
| 4' | 7.50, d (8.0) | 119.7 | 7.53, d (8.4) | 121.5 | 7.48, d (8.4) | 120.5 |
| 4a' | - | 133.6 | - | 134.2 | - | 134.2 |
| 5' | 7.52, d (8.0) | 120.1 | 7.49, d (8.4) | 120.5 | 7.53, d (8.4) | 121.4 |
| 6' | 7.45, t (7.6) | 127.5 | 7.43, t (8.0) | 127.1 | 7.42, t (7.6) | 127.1 |
| 7' | 6.94, d (7.2) | 108.8 | 6.95, d (7.2) | 109.6 | 6.93, d (7.6) | 109.6 |
| 8' | - | 147.6 | - | 145.9 | - | 145.9 |
| 8a' | - | 113.3 | - | 113.8 | - | 113.9 |
| 4-OH | 3.70, br s | - | - | - | - | - |
| 5-OH | 4.81, d (2.8) | - | - | - | - | - |
| 7-OH | 3.85, d (2.4) | - | - | - | - | - |
| 8-OH | 4.21, br s | - | 3.77, s | - | 3.71, s | - |
| 7-OMe | - | - | - | - | 3.43, s | 56.9 |
a Measured in DMSO-d6; b measured in CDCl3.
Figure 3ORTEP diagram of rhytidone B (2).
Figure 4ORTEP diagram of rhytidone C (3).
Cytotoxicity of compounds 2–5 against human breast and cervical cancer cell lines.
| Compound | IC50 (μM) | |
|---|---|---|
| MCF-7 | CaSki | |
|
| − a | 22.81 ± 1.33 |
|
| 17.30 ± 2.11 | 24.44 ± 0.22 |
|
| 20.10 ± 1.52 | 25.59 ± 1.70 |
|
| 14.47 ± 0.51 | 21.95 ± 2.56 |
| Doxorubicin | 0.06 ± 0.01 | 0.20 ± 0.02 |
a IC50 > 10 μg/mL.